Build Your Comparison

Side-by-side financial analysis
NYXH logo
NYXH
INSP logo
INSP
NVCR logo
NVCR
TNDM logo
TNDM
MDT logo
MDT
Try popular comparisons:

Stock Comparison

NYXH vs INSP vs NVCR vs TNDM vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NYXH
Nyxoah S.A.

Medical - Instruments & Supplies

HealthcareNASDAQ • BE
Market Cap$52M
5Y Perf.-94.2%
INSP
Inspire Medical Systems, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$1.23B
5Y Perf.-82.0%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.02B
5Y Perf.-91.3%
TNDM
Tandem Diabetes Care, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.14B
5Y Perf.-81.9%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • US
Market Cap$102.97B
5Y Perf.-38.7%

NYXH vs INSP vs NVCR vs TNDM vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NYXH logoNYXH
INSP logoINSP
NVCR logoNVCR
TNDM logoTNDM
MDT logoMDT
IndustryMedical - Instruments & SuppliesMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - Devices
Market Cap$52M$1.23B$2.02B$1.14B$102.97B
Revenue (TTM)$16M$915M$674M$1.03B$35.48B
Net Income (TTM)$-86M$131M$-173M$-95M$4.61B
Gross Margin48.3%85.8%75.2%54.9%61.9%
Operating Margin-5.3%5.6%-27.2%-7.9%17.9%
Forward P/E47.6x13.4x
Total Debt$42M$32M$290M$444M$28.52B
Cash & Equiv.$30M$105M$103M$91M$2.22B

NYXH vs INSP vs NVCR vs TNDM vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NYXH
INSP
NVCR
TNDM
MDT
StockApr 21Jun 26Return
Nyxoah S.A. (NYXH)1005.8-94.2%
Inspire Medical Sys… (INSP)10018.0-82.0%
NovoCure Limited (NVCR)1008.7-91.3%
Tandem Diabetes Car… (TNDM)10018.1-81.9%
Medtronic plc (MDT)10061.3-38.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: NYXH vs INSP vs NVCR vs TNDM vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Inspire Medical Systems, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. NYXH and NVCR also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
🥇MDT emerged as the overall leader. Track its performance:
NYXH
Nyxoah S.A.
The Growth Leader

NYXH ranks third and is worth considering specifically for growth.

  • 121.6% revenue growth vs MDT's 3.6%
Best for: growth
INSP
Inspire Medical Systems, Inc.
The Growth Play

INSP is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 13.6%, EPS growth 179.4%, 3Y rev CAGR 30.8%
  • 70.9% 10Y total return vs MDT's 21.2%
  • Lower volatility, beta 1.16, Low D/E 4.1%, current ratio 6.08x
  • Beta 1.16, current ratio 6.08x
Best for: growth exposure and long-term compounding
NVCR
NovoCure Limited
The Momentum Pick

NVCR is the clearest fit if your priority is momentum.

  • -2.3% vs NYXH's -81.6%
Best for: momentum
TNDM
Tandem Diabetes Care, Inc.
The Healthcare Pick

Among these 5 stocks, TNDM doesn't own a clear edge in any measured category.

Best for: healthcare exposure
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 44 yrs, beta 0.31, yield 3.5%
  • Better valuation composite
  • Beta 0.31 vs NVCR's 2.21, lower leverage
  • 3.5% yield; 44-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthNYXH logoNYXH121.6% revenue growth vs MDT's 3.6%
ValueMDT logoMDTBetter valuation composite
Quality / MarginsINSP logoINSP14.3% margin vs NYXH's -5.3%
Stability / SafetyMDT logoMDTBeta 0.31 vs NVCR's 2.21, lower leverage
DividendsMDT logoMDT3.5% yield; 44-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)NVCR logoNVCR-2.3% vs NYXH's -81.6%
Efficiency (ROA)INSP logoINSP15.2% ROA vs NYXH's -80.8%, ROIC 6.0% vs -76.4%

NYXH vs INSP vs NVCR vs TNDM vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the GLP-1 Stocks Theme

These companies are key players in the GLP-1 Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
NYXHNyxoah S.A.

Segment breakdown not available.

INSPInspire Medical Systems, Inc.
FY 2025
Operating Segment
100.0%$912M
NVCRNovoCure Limited

Segment breakdown not available.

TNDMTandem Diabetes Care, Inc.
FY 2025
Supplies and Other
54.3%$551M
Pump
45.7%$464M
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

NYXH vs INSP vs NVCR vs TNDM vs MDT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDTLAGGINGTNDM

Income & Cash Flow (Last 12 Months)

Evenly matched — INSP and MDT each lead in 2 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 2174.5x NYXH's $16M. INSP is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
RevenueTrailing 12 months$16M$915M$674M$1.0B$35.5B
EBITDAEarnings before interest/tax-$81M$62M-$165M-$68M$9.4B
Net IncomeAfter-tax profit-$86M$131M-$173M-$95M$4.6B
Free Cash FlowCash after capex-$73M$97M-$48M-$4M$5.4B
Gross MarginGross profit ÷ Revenue+48.3%+85.8%+75.2%+54.9%+61.9%
Operating MarginEBIT ÷ Revenue-5.3%+5.6%-27.2%-7.9%+17.9%
Net MarginNet income ÷ Revenue-5.3%+14.3%-25.7%-9.2%+13.0%
FCF MarginFCF ÷ Revenue-4.5%+10.6%-7.1%-0.4%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+5.9%+1.6%+12.3%+5.5%+8.8%
EPS Growth (YoY)Latest quarter vs prior year+38.3%-5.0%-100.0%+84.8%-11.9%
Evenly matched — INSP and MDT each lead in 2 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 2 of 6 comparable metrics.

At 8.7x trailing earnings, INSP trades at a 61% valuation discount to MDT's 22.2x P/E. On an enterprise value basis, MDT's 14.7x EV/EBITDA is more attractive than INSP's 17.8x.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
Market CapShares × price$52M$1.2B$2.0B$1.1B$103.0B
Enterprise ValueMkt cap + debt − cash$66M$1.2B$2.2B$1.5B$129.3B
Trailing P/EPrice ÷ TTM EPS-0.51x8.73x-14.57x-5.46x22.22x
Forward P/EPrice ÷ next-FY EPS est.47.59x13.44x
PEG RatioP/E ÷ EPS growth rate34.25x
EV / EBITDAEnterprise value multiple17.83x14.66x
Price / SalesMarket cap ÷ Revenue4.48x1.35x3.09x1.12x3.07x
Price / BookPrice ÷ Book value/share0.93x1.63x5.82x7.20x2.14x
Price / FCFMarket cap ÷ FCF15.68x19.86x
MDT leads this category, winning 2 of 6 comparable metrics.

Profitability & Efficiency

INSP leads this category, winning 7 of 9 comparable metrics.

INSP delivers a 18.0% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-164 for NYXH. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to TNDM's 2.86x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs NYXH's 2/9, reflecting strong financial health.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
ROE (TTM)Return on equity-164.4%+18.0%-50.8%-68.3%+9.5%
ROA (TTM)Return on assets-80.8%+15.2%-16.5%-10.0%+5.0%
ROICReturn on invested capital-76.4%+6.0%-16.4%-10.0%+6.0%
ROCEReturn on capital employed-80.4%+6.7%-28.9%-11.5%+7.5%
Piotroski ScoreFundamental quality 0–927536
Debt / EquityFinancial leverage0.86x0.04x0.85x2.86x0.59x
Net DebtTotal debt minus cash$12M-$73M$187M$354M$26.3B
Cash & Equiv.Liquid assets$30M$105M$103M$91M$2.2B
Total DebtShort + long-term debt$42M$32M$290M$444M$28.5B
Interest CoverageEBIT ÷ Interest expense-32.73x418.58x-96.80x-19.88x8.81x
INSP leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MDT leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MDT five years ago would be worth $7,559 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, NVCR leads with a -2.3% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors MDT at 1.7% vs INSP's -48.0% — a key indicator of consistent wealth creation.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
YTD ReturnYear-to-date-69.1%-53.7%+35.5%-23.0%-15.8%
1-Year ReturnPast 12 months-81.6%-66.8%-2.3%-20.7%-6.2%
3-Year ReturnCumulative with dividends-82.4%-85.9%-59.8%-35.9%+5.1%
5-Year ReturnCumulative with dividends-94.9%-77.3%-91.9%-82.1%-24.4%
10-Year ReturnCumulative with dividends-94.2%+70.9%+62.1%-77.0%+21.2%
CAGR (3Y)Annualised 3-year return-44.0%-48.0%-26.2%-13.8%+1.7%
MDT leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — NVCR and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than NVCR's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 94.0% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5002.10x1.16x2.21x1.26x0.31x
52-Week HighHighest price in past year$8.59$147.03$18.92$29.65$106.33
52-Week LowLowest price in past year$1.26$38.91$9.82$9.98$73.31
% of 52W HighCurrent price vs 52-week peak+16.2%+29.0%+94.0%+56.0%+75.4%
RSI (14)Momentum oscillator 0–10025.843.357.143.253.7
Avg Volume (50D)Average daily shares traded189K950K1.5M2.3M9.2M
Evenly matched — NVCR and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 1 of 1 comparable metric.

Analyst consensus: NYXH as "Buy", INSP as "Hold", NVCR as "Buy", TNDM as "Buy", MDT as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs 20.4% for MDT (target: $97). MDT is the only dividend payer here at 3.47% yield — a key consideration for income-focused portfolios.

MetricNYXH logoNYXHNyxoah S.A.INSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuyBuy
Price TargetConsensus 12-month target$6.00$57.36$33.50$31.46$96.57
# AnalystsCovering analysts527153951
Dividend YieldAnnual dividend ÷ price+3.5%
Dividend StreakConsecutive years of raises044
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap0.0%+14.2%0.0%0.0%+3.1%
MDT leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MDT leads in 3 of 6 categories (Valuation Metrics, Total Returns). INSP leads in 1 (Profitability & Efficiency). 2 tied.

Best OverallMedtronic plc (MDT)Leads 3 of 6 categories
Loading custom metrics...

NYXH vs INSP vs NVCR vs TNDM vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NYXH or INSP or NVCR or TNDM or MDT a better buy right now?

For growth investors, Nyxoah S.

A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 8. 7x trailing P/E (47. 6x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NYXH or INSP or NVCR or TNDM or MDT?

On trailing P/E, Inspire Medical Systems, Inc.

(INSP) is the cheapest at 8. 7x versus Medtronic plc at 22. 2x. On forward P/E, Medtronic plc is actually cheaper at 13. 4x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — NYXH or INSP or NVCR or TNDM or MDT?

Over the past 5 years, Medtronic plc (MDT) delivered a total return of -24.

4%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: INSP returned +70. 9% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NYXH or INSP or NVCR or TNDM or MDT?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

31β versus NovoCure Limited's 2. 21β — meaning NVCR is approximately 615% more volatile than MDT relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NYXH or INSP or NVCR or TNDM or MDT?

By revenue growth (latest reported year), Nyxoah S.

A. (NYXH) is pulling ahead at 121. 6% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NYXH or INSP or NVCR or TNDM or MDT?

Inspire Medical Systems, Inc.

(INSP) is the more profitable company, earning 15. 9% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 15. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NYXH or INSP or NVCR or TNDM or MDT more undervalued right now?

On forward earnings alone, Medtronic plc (MDT) trades at 13.

4x forward P/E versus 47. 6x for Inspire Medical Systems, Inc. — 34. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.

08

Which pays a better dividend — NYXH or INSP or NVCR or TNDM or MDT?

In this comparison, MDT (3.

5% yield) pays a dividend. NYXH, INSP, NVCR, TNDM do not pay a meaningful dividend and should not be held primarily for income.

09

Is NYXH or INSP or NVCR or TNDM or MDT better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

31), 3. 5% yield). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +21. 2%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NYXH and INSP and NVCR and TNDM and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NYXH is a small-cap high-growth stock; INSP is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; TNDM is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while NYXH, INSP, NVCR, TNDM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.